Nuvectis Pharma, Inc. (NVCT) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Nuvectis Pharma, Inc.

NVCT

NASDAQ

Unprofitable

Unprofitable

163M

Biotechnology

Next Earning date - 13 Nov 2024

163M

Biotechnology

Next Earning date - 13 Nov 2024

8.76USD

0.01 ( 0.11%)

Relative Strenght

7

Volume Buzz

-16%

Earning Acce

No

Dist 52w H.

28%

Quote Panel

Updated October 26, 2024

1W 13.91 % 1M 41.75 % 3M 34.15 % 1Y 3.79 %

Key Metrics

Market Cap
163.40M
Shares Outstanding
18.65M
Share in Float
7.65M
Dividende
0

Earning Date
13 Nov 2024
Price Target
8.76
Average Volume
108510
Beta
0.449

Range
5.85-12.1
Industry
Biotechnology
Website
https://www.nuvectis.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

Nanx

P/S Ratio

11.82x

P/B Ratio

0.0

Debt/Equity

514.6%

Net Margin

$-1.3

EPS

How NVCT compares to sector?

P/E Ratio

Relative Strength

NVCT

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$23M

NaN%

2025-Revenue

$1.04

-301%

2025-EPS

$12M

348%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.42
vs -0.40

Q4.22

N/A

-0.48
vs -0.48

Q1.23

N/A

-0.27
vs -0.32

Q2.23

N/A

-0.38
vs -0.28

Q3.23

N/A

-0.37
vs -0.42

Q4.23

N/A

-0.41
vs -0.48

Q1.24

N/A

-0.25
vs -0.27

Q2.24

N/A

-0.26
vs -0.38

Q3.24

N/A

-0.25
vs -0.37

Q4.24

N/A

-0.27
vs -0.41

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

+3625%

149K vs 4K

Q1.23

NA

4.1M vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

-2852%

-4101000.00 vs 149K

Q1.24

-100%

NA vs 4.1M

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

-29%

-0.29
vs -0.31

Q4.22

-46%

-0.46
vs -0.29

Q1.23

-33%

-0.33
vs -0.46

Q2.23

-28%

-0.28
vs -0.33

Q3.23

-35%

-0.35
vs -0.28

Q4.23

-54%

-0.54
vs -0.35

Q1.24

-30%

-0.30
vs -0.54

Q2.24

-35%

-0.35
vs -0.30

Institutionnal Ownership

QoQ

Q3.22

11

11
vs 10

10%

Q4.22

11

11
vs 11

NA

Q1.23

13

13
vs 11

18%

Q2.23

37

37
vs 13

185%

Q3.23

33

33
vs 37

-11%

Q4.23

36

36
vs 33

9%

Q1.24

40

40
vs 36

11%

Q2.24

38

38
vs 40

-5%

Earnings Growth

Latest News

NVCT

investorplace.com

6 hours ago

7 Penny Biotech Stocks to Triple Your Investment

NVCT

globenewswire.com

8 hours ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

NVCT

globenewswire.com

8 hours ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

NVCT

globenewswire.com

8 hours ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

NVCT

globenewswire.com

8 hours ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

NVCT

zacks.com

10 hours ago

Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

New Feature Coming Soon, Stay Tuned!

Shape

Shape